课题基金 / 基金详情

FASEB SUMMER RESEARCH CONF.--LYMPHOCYTES AND ANTIBODIES

FASEB SUMMER RESEARCH CONF.--LYMPHOCYTES AND ANTIBODIES
FASEB 夏季研究会议——淋巴细胞和抗体
批准号:
3434292
负责人:
LAURIE Hollis GLIMCHER
金额:
$1.0万
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-05-20 至 1994-05-19

项目摘要

项目成果

LAURIE Hollis GLIMCHER的其他基金

相似基金

相关文献

中文摘要
翻译
1993年夏季FASE B研究会议,淋巴细胞和抗体, 6月5日至10日,将与少数人举行密集会议 参与者(约155人),将涵盖极端主题 引起了免疫生物学家的兴趣。考虑到缺乏其他基本的 在紧随其后的几个月内召开免疫学会议 FASEB会议(没有戈登会议或国际免疫学 研讨会),我们期望演讲者和科学的质量 要非常高。此外,我们已经与大卫·哈夫勒博士安排了 将夏季FASE B自身免疫研究会议与 回到我们更基本的会议,希望参加的个人 两次会议都可以做到这一点。
英文摘要
The 1993 Summer FASEB Research Conference, Lymphocytes and Antibodies, June 5th to 10th, will be an intensive meeting with a small number of participants (approximately 155) which will cover topics of extreme interest to immunobiologists. Given the lack of other basic immunology-oriented meetings in the months immediately pre and post the FASEB meeting (no Gordon Conference or International Immunology Symposium), we expect the quality of the speakers and of the science to be extremely high. Furthermore, we have arranged with Dr. David Hafler to juxtapose the summer FASEB Autoimmunity Research Conference back to back with our more basic meeting so that individuals who wish to attend both meetings can do so.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Developing a pragmatic guide to implementing social risk referrals: A partnership between Caring Health Center (CHC) and the Implementation Science Center for Cancer
  • 批准号:
    10822141
  • 项目类别:
  • 资助金额:
    $22.47万
  • 财政年份:
    2023
  • 负责人:
    LAURIE Hollis GLIMCHER
  • 依托单位:
Understanding the impact of an EHR-integrated hereditary cancer risk assessment application on patient-provider communication
  • 批准号:
    10831167
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    2023
  • 负责人:
    LAURIE Hollis GLIMCHER
  • 依托单位:
Real-World Molecularly Targeted Treatment Registry (MaTTeR): a Pilot Study to Enrich CCDI Data Utilizing Directed Electronic Medical Record (EMR) Extraction
  • 批准号:
    10878384
  • 项目类别:
  • 资助金额:
    $49.59万
  • 财政年份:
    2023
  • 负责人:
    LAURIE Hollis GLIMCHER
  • 依托单位:
Repurposing Bruton's tyrosine kinase (BTK) inhibitors to reverse immunosuppression in high-grade serous ovarian cancer (HGSC)
  • 批准号:
    10661823
  • 项目类别:
  • 资助金额:
    $8.9万
  • 财政年份:
    2022
  • 负责人:
    LAURIE Hollis GLIMCHER
  • 依托单位:
海外基金